Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: G04BE08

Adcirca (previously Tadalafil Lilly)(tadalafil)

Hypertension, Pulmonary

Marketing Authorisation Holder: Eli Lilly Nederland B.V.

EMA Authorisation: 01/10/2008

INN: tadalafil

Indication

AdultsTreatment of pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity (see section 5.1). Efficacy has been shown in idiopathic PAH (IPAH) and in PAH related to collagen vascular disease. Paediatric populationTreatment of paediatric patients aged 2 years and above with pulmonary arterial hypertension (PAH) classified as WHO functional class II and III.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Adcirca (previously Tadalafil Lilly) — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Ask about Adcirca (previously Tadalafil Lilly)Create Free Account

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.